Valuation: Sarepta Therapeutics, Inc.

Capitalization 10.46B 9.95B 9.39B 8.29B 14.81B 906B 16.44B 112B 41.41B 379B 39.19B 38.41B 1,590B P/E ratio 2024 *
40.8x
P/E ratio 2025 * 10.4x
Enterprise value 9.73B 9.26B 8.74B 7.72B 13.78B 843B 15.3B 104B 38.54B 352B 36.47B 35.74B 1,479B EV / Sales 2024 *
5.28x
EV / Sales 2025 * 2.61x
Free-Float
95.63%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart

Last Transcript: Sarepta Therapeutics, Inc.

1 day-0.98%
1 week-3.14%
Current month-4.76%
1 month-8.85%
3 months-0.73%
6 months-18.61%
Current year-10.92%
More quotes
1 week
107.61
Extreme 107.61
114.41
1 month
107.61
Extreme 107.61
123.02
Current year
107.61
Extreme 107.61
129.84
1 year
102.16
Extreme 102.155
173.25
3 years
55.25
Extreme 55.25
173.25
5 years
55.25
Extreme 55.25
181.83
10 years
8.00
Extreme 8
181.83
More quotes
Director TitleAgeSince
Chief Executive Officer 62 2017-06-25
Director of Finance/CFO 49 2020-12-13
Chief Tech/Sci/R&D Officer - 2022-12-30
Manager TitleAgeSince
Chairman 72 2015-04-15
Director/Board Member 87 2010-05-31
Director/Board Member 66 2015-06-01
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-0.96%-3.14%-12.86%+37.75% 10.46B
-0.61%-1.79%+10.30%+99.33% 119B
+0.31%-4.89%-28.76%+8.30% 72.16B
-2.13%-3.83%+68.23%+140.90% 39.41B
-3.23%+1.47%+30.48%-22.78% 29.44B
+2.55%+3.57%+58.70%+12.76% 24.06B
+4.61%+2.46%+11.97%-28.40% 22.32B
-1.76%+6.71%+382.25%+957.14% 16.09B
-0.15%-1.74%+186.30%+241.57% 14.07B
+0.94%+8.59%-19.89%-31.61% 13.26B
Average -0.07%-0.33%+68.67%+141.50% 36.01B
Weighted average by Cap. -0.28%-2.50%+35.51%+99.24%
See all sector performances

Financials

2024 *2025 *
Net sales 1.84B 1.75B 1.65B 1.46B 2.61B 160B 2.9B 19.69B 7.3B 66.72B 6.9B 6.77B 280B 3.16B 3.01B 2.84B 2.51B 4.48B 274B 4.97B 33.8B 12.52B 115B 11.85B 11.61B 481B
Net income 256M 244M 230M 203M 363M 22.17B 402M 2.74B 1.01B 9.27B 959M 940M 38.92B 1.12B 1.06B 1B 885M 1.58B 96.67B 1.75B 11.93B 4.42B 40.42B 4.18B 4.1B 170B
Net Debt -726M -691M -652M -576M -1.03B -62.92B -1.14B -7.77B -2.88B -26.31B -2.72B -2.67B -110B -2.2B -2.1B -1.98B -1.75B -3.12B -191B -3.46B -23.55B -8.73B -79.8B -8.26B -8.09B -335B
More financial data * Estimated data
Logo Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
Employees
1,314
Calendar
More about the company
Date Price Change Volume
25-02-14 108.30 $ -1.06% 320,812
25-02-13 109.46 $ -0.32% 712,626
25-02-12 109.81 $ +0.12% 639,621
25-02-11 109.68 $ -2.71% 654,227
25-02-10 112.74 $ +0.82% 604,097

Delayed Quote Nasdaq, February 14, 2025 at 01:05 pm EST

More quotes
Trading Rating
Investor Rating
ESG MSCI
BBB
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
109.46USD
Average target price
181.78USD
Spread / Average Target
+66.07%
Consensus

Quarterly revenue - Rate of surprise